CDNA
Price
$20.37
Change
-$1.77 (-7.99%)
Updated
Dec 18, 04:59 PM (EDT)
69 days until earnings call
PLSE
Price
$17.75
Change
-$1.49 (-7.74%)
Updated
Dec 18, 04:59 PM (EDT)
98 days until earnings call
Ad is loading...

CDNA vs PLSE

Header iconCDNA vs PLSE Comparison
Open Charts CDNA vs PLSEBanner chart's image
CareDx
Price$20.37
Change-$1.77 (-7.99%)
Volume$29.12K
CapitalizationN/A
Pulse Biosciences
Price$17.75
Change-$1.49 (-7.74%)
Volume$1.74K
CapitalizationN/A
CDNA vs PLSE Comparison Chart
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. PLSE commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Hold and PLSE is a Buy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (CDNA: $22.14 vs. PLSE: $19.24)
Brand notoriety: CDNA and PLSE are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 85% vs. PLSE: 89%
Market capitalization -- CDNA: $548.33M vs. PLSE: $481.01M
CDNA [@Medical Specialties] is valued at $548.33M. PLSE’s [@Medical Specialties] market capitalization is $481.01M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 1 FA rating(s) are green whilePLSE’s FA Score has 0 green FA rating(s).

  • CDNA’s FA Score: 1 green, 4 red.
  • PLSE’s FA Score: 0 green, 5 red.
According to our system of comparison, CDNA is a better buy in the long-term than PLSE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 4 TA indicator(s) are bullish while PLSE’s TA Score has 5 bullish TA indicator(s).

  • CDNA’s TA Score: 4 bullish, 4 bearish.
  • PLSE’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CDNA and PLSE are a good buy in the short-term.

Price Growth

CDNA (@Medical Specialties) experienced а -8.02% price change this week, while PLSE (@Medical Specialties) price change was +15.42% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.22%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +1.33%.

Reported Earning Dates

CDNA is expected to report earnings on Feb 26, 2025.

PLSE is expected to report earnings on Mar 27, 2025.

Industries' Descriptions

@Medical Specialties (-4.22% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($548M) has a higher market cap than PLSE($481M). CDNA YTD gains are higher at: 84.500 vs. PLSE (57.190). PLSE has higher annual earnings (EBITDA): -42.37M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. PLSE (44.4M). PLSE has less debt than CDNA: PLSE (9.14M) vs CDNA (34.2M). CDNA has higher revenues than PLSE: CDNA (280M) vs PLSE (0).
CDNAPLSECDNA / PLSE
Capitalization548M481M114%
EBITDA-84.92M-42.37M200%
Gain YTD84.50057.190148%
P/E RatioN/AN/A-
Revenue280M0-
Total Cash235M44.4M529%
Total Debt34.2M9.14M374%
FUNDAMENTALS RATINGS
CDNA vs PLSE: Fundamental Ratings
CDNA
PLSE
OUTLOOK RATING
1..100
7114
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
9583
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3938
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PLSE's Valuation (60) in the Medical Specialties industry is somewhat better than the same rating for CDNA (100). This means that PLSE’s stock grew somewhat faster than CDNA’s over the last 12 months.

PLSE's Profit vs Risk Rating (83) in the Medical Specialties industry is in the same range as CDNA (95). This means that PLSE’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's SMR Rating (97) in the Medical Specialties industry is in the same range as PLSE (98). This means that CDNA’s stock grew similarly to PLSE’s over the last 12 months.

PLSE's Price Growth Rating (38) in the Medical Specialties industry is in the same range as CDNA (39). This means that PLSE’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's P/E Growth Rating (1) in the Medical Specialties industry is significantly better than the same rating for PLSE (100). This means that CDNA’s stock grew significantly faster than PLSE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAPLSE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 9 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLSE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with LH. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then LH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-3.19%
LH - CDNA
45%
Loosely correlated
+0.58%
MTD - CDNA
45%
Loosely correlated
-1.10%
VCYT - CDNA
44%
Loosely correlated
-2.52%
BLFS - CDNA
41%
Loosely correlated
-1.83%
TMO - CDNA
40%
Loosely correlated
-0.27%
More

PLSE and

Correlation & Price change

A.I.dvisor tells us that PLSE and CERS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLSE and CERS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLSE
1D Price
Change %
PLSE100%
+0.37%
CERS - PLSE
32%
Poorly correlated
-6.11%
CDNA - PLSE
29%
Poorly correlated
-3.19%
CTKB - PLSE
27%
Poorly correlated
-2.28%
INMD - PLSE
26%
Poorly correlated
-0.78%
MASS - PLSE
26%
Poorly correlated
-5.58%
More